Beacon Pharmaceuticals has registered a marginal growth in earnings per share for the fiscal 2021-22 compared to the previous year.
The EPS rose 8.28 per cent to Tk 4.05 from the last fiscal year.
The company, however, attained a robust growth in cash flow, mainly because of its "sales-on-cash-only" policy. The net operating cash flow per share jumped 450.58 per cent year-on-year to Tk 4.68 in the fiscal 2021-22.
"Sales during April-June fell a bit. Otherwise, the company could register higher growth in earnings," said Khalilur Rahman, company secretary.
"We have reduced our operating costs. Besides, we have come out of business on credit," he added.
Meanwhile, the company's board of directors has recommended 16 per cent cash dividend for the fiscal 2021-22.
Beacon Pharmaceuticals, presently an 'A' category company, was listed with the bourses in 2010.
Sponsor-directors hold 30 per cent shares, institutes 36.09 per cent and foreigners 33.91 per cent as of September 30, 2022.
The share price closed at Tk 323.90 on Wednesday, having recorded a rise of 2.34 per cent or Tk 7.40.
Presently, 17 pharmaceutical companies are listed with the bourses under the pharmaceutical and chemical sector comprising 18 percent share of the market capitalisation.
